Clinical analysis of permanent 125I prostate brachytherapy monotherapy for early prostate cancer ( report of 18 cases)
10.3760/cma.j.issn.1000-6702.2012.01.017
- VernacularTitle:单纯125I放射性粒子植入治疗早期前列腺癌的临床分析
- Author:
Zhicao ZHANG
;
Yi HUANG
;
Lulin MA
;
Fan ZHANG
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Carcinoma;
125I brachytherapy
- From:
Chinese Journal of Urology
2012;33(1):55-57
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy of permanent 125I prostate brachytherapy monotherapy in patients with early prostate cancer. Methods A total of 18 patients with prostate cancer was diagnosed by prostate biopsy,with Gleason score 5 - 6,average PSA 5.09 ng/ml (range,0.38 -8.73 ),and clinical stage T1c - T2a.All patients underwent 3-dimensional conformal brachytherapy with transperineal ultrasound-guide 125I seeds prostate implantation. Results None of the patients had any adverse events during the operation processes.The operation time was from 37 to 52 minutes and postoperative hospitalization time was from 3 to 4 days.The mean number of implanted 125I seeds was 54.All patients were followed up for 3 to 57 months with a mean of 15 months,while one patient was lost during followingup.The survival rate of PSA progression free was 100％ (17/17).The PSA was under 0.2 ng/ml for a long time in the 7 cases who had been followed-up for more than 18 months.The PSA did not show any rising trend in all 17 cases.No severe complications occurred in all cases. Conclusions Brachytherapy monotherapy with 125I seeds implantation is safe and effective for patients with early prostate cancer.
